CN102342995A - Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof - Google Patents
Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof Download PDFInfo
- Publication number
- CN102342995A CN102342995A CN2010102454960A CN201010245496A CN102342995A CN 102342995 A CN102342995 A CN 102342995A CN 2010102454960 A CN2010102454960 A CN 2010102454960A CN 201010245496 A CN201010245496 A CN 201010245496A CN 102342995 A CN102342995 A CN 102342995A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- compositions
- ethanol
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medicinal composition for treating liver cirrhosis and liver ascites and a preparation method thereof, wherein the medicinal composition comprises the following components: American ginseng, Savia miltiorrhiza, radix bupleuri, Schisandra chinensis, Rhizoma Polygoni Cuspidati, Isatidis Radix, Hedyotis Diffusa Willd., bear gall, and egg oil. The invention also discloses a preparation method of the medicinal composition by mixing extracts which are extracted from American ginseng, Savia miltiorrhiza, and radix bupleuri through a special extraction process with other components processed with a routine process. A dripping pill for example, prepared from the medicinal composition provided in the invention, is a medicine with the functions of right supporting and root securing, qi benefiting and yin nourishing, blood circulation promoting and blood stasis removing, heat clearing and detoxifying, tumor inhibiting, and liver fibrosis preventing, the cure rate and the effective rate of the dripping pill on liver cirrhosis and liver ascites are 80% and 95% respectively, and the cure rate and the effective rate of the dripping pill on liver cancers are 60% and 80% respectively.
Description
Technical field
The present invention relates to a kind of medicine of treating liver cirrhosis, hepatic ascites, hepatocarcinoma, specifically relate to a kind of pharmaceutical composition and method for preparing of treating liver cirrhosis, hepatic ascites, hepatocarcinoma.
Background technology
Liver cirrhosis, hepatic ascites, hepatocarcinoma are that a kind of infectious rate, mortality rate occupy first of 25 kinds of Category B notifiable diseases of China.Someone estimates that China has 1.3 hundred million people to carry hepatitis B virus; There is 80% people to need treatment; Wherein 25% people develops into liver cirrhosis, hepatic ascites, hepatocarcinoma, dies from nearly 2,000,000 people of patient of liver cirrhosis, hepatic ascites, hepatocarcinoma every year, and therefore saying should disease serious harm human health.The treatment of this disease is an a great problem in the world today, so far the ideal medicine of neither one.
Summary of the invention
The pharmaceutical composition that the purpose of this invention is to provide the treating both the principal and secondary aspects of a disease of a kind of treatment liver cirrhosis, hepatic ascites, hepatocarcinoma with strengthening the body resistance, supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling, heat-clearing and toxic substances removing, eliminating damp-heat, anti-hepatic fibrosis, the purposes of said preparation of compositions method and the capsule that is used to prepare treatment liver cirrhosis, hepatic ascites, hepatocarcinoma, tablet, drop pill, granule, pill, oral liquid, slow releasing agent, freeze dried powder etc.Wherein utilize American ginseng total saponins it is cold in nature, bitter but slightly sweet taste, be longer than boosting qi and nourishing yin, relieve inflammation or internal heat and promote the production of body fluid, rectify and set upright the effect of gas.Experiment proof Radix Panacis Quinquefolii saponin Rb
1Can suppress virus, protection infection cell, Radix Panacis Quinquefolii saponin R
oAcute and chronic inflammation all there is remarkable inhibitory action.Radix Panacis Quinquefolii saponin R
dPromote that the anabolic effect of serum albumin matter is the strongest.Utilize Tanshinone I Ia bitter in the mouth, cold nature, merit are arrogated to oneself current blood vessels, blood circulation promoting and blood stasis dispelling, but the effect of heat clearing and blood cooling again; Moreover also utilize flat, the fragrant catharsis of Radix Bupleuri total saponin bitter in the mouth property, but depressed liver-energy dispersing and QI regulating, the effect of orderly and clearly mechanism of qi.Also utilize the handsome blood of Tanshinone I Ia and American ginseng total saponins gas capable, the effect of the meaning of useful qi and blood circulation promotion; Utilize the capable then blood of Tanshinone I Ia and Radix Bupleuri total saponin gas capable, the effect of promoting flow of QI and blood is arranged.These monarch-minister drugs match, and make gas because of saving the state, and mechanism of qi a surname is smooth, and the venation tonneau is in order to clearing away the dampness and heat.Rhizoma Polygoni Cuspidati ethanol extract, Herba Hedyotidis Diffusae ethanol extract as adjuvant drug have heat-clearing and toxic substances removing, the effect of blood stasis dispelling dehumidifying.
Monarch, minister in the pharmaceutical composition provided by the invention, help, make and match; The pharmaceutical composition that a large amount of evidence applications that the applicant did are awaited the reply had both met the Chinese medicine traditional theory; Embody the Chinese medicine unique distinction of treating both the principal and secondary aspects of a disease, meet the modern medicine and pharmacology theory again.Use Tanshinone I Ia, the ethanol extract of Rhizoma Polygoni Cuspidati, Herba Hedyotidis Diffusae, antitumor such as Fel Ursi, heat-clearing and toxic substances removing.Utilize American ginseng total saponins mediator body immunity function, with Radix Bupleuri total saponin, Fructus Schisandrae Chinensis total lignanoid protection hepatocyte.Utilize Tanshinone I Ia, Radix Bupleuri total saponin, Ovum Gallus domesticus Flavus lecithin blood circulation promoting and blood stasis dispelling, anti-hepatic fibrosis, thereby reach the purpose of Comprehensive Treatment liver cirrhosis, hepatic ascites, hepatocarcinoma.
A large amount of evidence pharmaceutical compositions provided by the invention are compositions usefuls of a kind of disease that cures difficult and complicated cases.
The purpose of this invention is to provide a kind of composition and method of making the same of treating cirrhosis, liver ascites, said compositions comprises following compositions by weight:
6～26 parts of 14～34 parts of Radix Bupleuri of 10～30 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
2～10 parts of 2～12 parts of Radix Isatidis of 4～24 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.6～1.4 part of 0.6～1.4 part of egg oil of 6～16 parts of Fel Ursis of Herba Hedyotidis Diffusae.
A further object of the present invention provides a kind of pharmaceutical composition and method for preparing of preferred therapeutic cirrhosis, liver ascites, and said compositions comprises following compositions by weight:
11～21 parts of 19～29 parts of Radix Bupleuri of 15～25 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～8 parts of 6～8 parts of Radix Isatidis of 9～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 0.8～1.2 part of egg oil of 15～25 parts of Fel Ursis of Herba Hedyotidis Diffusae.
The 3rd purpose of the present invention provides a kind of pharmaceutical composition of more preferably treating cirrhosis, liver ascites and preparation method thereof, and said compositions comprises following compositions by weight:
11～18 parts of 19～28 parts of Radix Bupleuri of 17～25 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～8 parts of 6～8 parts of Radix Isatidis of 11～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 0.8～1.2 part of egg oil of 15～25 parts of Fel Ursis of Herba Hedyotidis Diffusae.
The 4th purpose of the present invention provides pharmaceutical composition of a kind of most preferred treatment cirrhosis, liver ascites and preparation method thereof, and said compositions comprises following compositions by weight:
11～21 parts of 19～29 parts of Radix Bupleuri of 15～20 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～6 parts of 6～8 parts of Radix Isatidis of 9～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 1.0～1.2 parts of egg oil of 15～18 parts of Fel Ursis of Herba Hedyotidis Diffusae.
The 5th purpose of the present invention is to utilize aforementioned pharmaceutical compositions to process such as drop pill, tablet, pill, capsule, granule and oral liquid, slow releasing agent, freeze dried powder.
The present invention also provides a kind of method for preparing said pharmaceutical composition, and except that Radix Panacis Quinquefolii, Radix Salviae Miltiorrhizae and Radix Bupleuri adopted following method processing, other composition was all handled by universal method.The Radix Panacis Quinquefolii alcohol reflux filters extracting solution, D on decompression recycling ethanol to the fluid extract
101Macroporous resin, ethanol elution, the eluent decompression recycling ethanol concentrates, is lyophilized into fine powder; Radix Salviae Miltiorrhizae, each 1.5 hours, is collected decompression filtrate recycling ethanol and is concentrated into fluid extract, is lyophilized into fine powder at 45-65 ℃ of following reduced-pressure backflow with ethanol; Radix Bupleuri alkaline ethanol reduced-pressure backflow, get filtrating decompression recycling ethanol below 60 ℃ after 4 ℃ of cold room cold preservation, get the deposition cold drying become fine powder.
In the pharmaceutical composition preferred for preparation method of the present invention, Radix Panacis Quinquefolii, Radix Salviae Miltiorrhizae and Radix Bupleuri are handled as follows: Radix Panacis Quinquefolii each 1-2 hour, filters extracting solution, D on decompression recycling ethanol to the fluid extract with 65-85% alcohol reflux 3 times
101Macroporous resin is used the 40-60% ethanol elution, the eluent decompression recycling ethanol be concentrated into relative density be behind the 1.31-1.33-50 ℃ be lyophilized into fine powder.Radix Salviae Miltiorrhizae, was collected filtrating in each 1.5 hours and is concentrated into fluid extract at 50-70 ℃ of following decompression recycling ethanol and under-40-60 ℃, is lyophilized into fine powder 45-65 ℃ of following reduced-pressure backflow 3 times with ethanol.Radix Bupleuri 75-85 ℃ of following reduced-pressure backflow 3 times, each 1-2 hour, is got filtrating at 60 ℃ of following decompression recycling ethanols to 1: 1 (crude drug amount: water-soluble liquid measure) get the deposition cold drying after 24 hours 4 ℃ of cold room cold preservations and become fine powder with the 70-80% alkaline ethanol.
Rhizoma Polygoni Cuspidati, Herba Hedyotidis Diffusae, Radix Isatidis and Fructus Schisandrae Chinensis adopt universal method to extract.Universal method in this description is an alcohol extracting-water precipitating.
Claims (8)
1. compositions of treating cirrhosis, liver ascites is characterized in that said compositions processed by following raw material medicaments by weight:
6～26 parts of 14～34 parts of Radix Bupleuri of 10～30 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
2～10 parts of 2～12 parts of Radix Isatidis of 4～24 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.6～1.4 part of 0.6～1.4 part of egg oil of 6～16 parts of Fel Ursis of Herba Hedyotidis Diffusae.
2. according to the compositions of claim 1, it is characterized in that said compositions processed by following raw material medicaments by weight:
11～21 parts of 19～29 parts of Radix Bupleuri of 15～25 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～8 parts of 6～8 parts of Radix Isatidis of 9～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 0.8～1.2 part of egg oil of 9～15 parts of Fel Ursis of Herba Hedyotidis Diffusae.
3. according to the compositions of claim 1 or 2, it is characterized in that said compositions processed by following raw material medicaments by weight:
11～14 parts of 19～28 parts of Radix Bupleuri of 17～25 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～8 parts of 6～8 parts of Radix Isatidis of 10～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 0.8～1.2 part of egg oil of 10～14 parts of Fel Ursis of Herba Hedyotidis Diffusae
4. according to the compositions of claim 3, it is characterized in that said compositions processed by following raw material medicaments by weight:
12～13 parts of 19～27 parts of Radix Bupleuri of 15～20 parts of Radix Salviae Miltiorrhizaes of Radix Panacis Quinquefolii
4～6 parts of 6～8 parts of Radix Isatidis of 9～19 parts of Rhizoma Polygoni Cuspidati of Fructus Schisandrae Chinensis
0.8～1.2 part of 1.0～1.2 parts of egg oil of 13～14 parts of Fel Ursis of Herba Hedyotidis Diffusae.
5. utilize the clinical acceptable drop pill of treatment cirrhosis, liver ascites, capsule, tablet, granule, oral liquid, pill, slow releasing agent, freeze dried powder any of the preparation of pharmaceutical compositions of the arbitrary claim of above-mentioned 1-4.
6. arbitrary preparation of drug combination method among the claim 1-4 is characterized in that, except that Radix Panacis Quinquefolii, Radix Salviae Miltiorrhizae and Radix Bupleuri adopted following method processing, other composition was all handled by universal method; The Radix Panacis Quinquefolii alcohol reflux filters extracting solution, D on decompression recycling ethanol to the fluid extract
101Macroporous resin, ethanol elution, the eluent decompression recycling ethanol concentrates, is lyophilized into fine powder; Radix Salviae Miltiorrhizae, each 1.5 hours, is collected decompression filtrate recycling ethanol and is concentrated into fluid extract, is lyophilized into fine powder at 45-65 ℃ of following reduced-pressure backflow with ethanol; Radix Bupleuri alkaline ethanol reduced-pressure backflow, get filtrating decompression recycling ethanol below 60 ℃ after 4 ℃ of cold room cold preservation, get the deposition cold drying become fine powder.
7. according to the preparation of drug combination method of claim 6; It is characterized in that; In the pharmaceutical composition preferred for preparation method of the present invention; Radix Panacis Quinquefolii, Radix Salviae Miltiorrhizae and Radix Bupleuri are handled as follows: Radix Panacis Quinquefolii is with 65-85% alcohol reflux 3 times; Each 1-2 hour; Filter extracting solution, D on decompression recycling ethanol to the fluid extract
101Macroporous resin is used the 40-60% ethanol elution, the eluent decompression recycling ethanol be concentrated into relative density be behind the 1.31-1.33-50 ℃ be lyophilized into fine powder.Radix Salviae Miltiorrhizae, was collected filtrating in each 1.5 hours and is concentrated into fluid extract at 50-70 ℃ of following decompression recycling ethanol and under-40-60 ℃, is lyophilized into fine powder 45-65 ℃ of following reduced-pressure backflow 3 times with ethanol.Radix Bupleuri 75-85 ℃ of following reduced-pressure backflow 3 times, each 1-2 hour, is got filtrating at 60 ℃ of following decompression recycling ethanols to 1: 1 (crude drug amount: water-soluble liquid measure) get the deposition cold drying after 24 hours 4 ℃ of cold room cold preservations and become fine powder with the 70-80% alkaline ethanol.
8. arbitrary compositions is being used for preparing the purposes of treating the cirrhosis, liver ascites medicine among the claim 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102454960A CN102342995A (en) | 2010-08-05 | 2010-08-05 | Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102454960A CN102342995A (en) | 2010-08-05 | 2010-08-05 | Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102342995A true CN102342995A (en) | 2012-02-08 |
Family
ID=45542316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102454960A Pending CN102342995A (en) | 2010-08-05 | 2010-08-05 | Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102342995A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3015112A4 (en) * | 2013-11-27 | 2016-06-22 | Mingjie Liu | Medicament for treatment of hepatic ascites and preparation method therefor |
| CN116350695A (en) * | 2023-05-16 | 2023-06-30 | 杨洪印 | New use of pharmaceutical composition for treating pulmonary nodules |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903276A (en) * | 2006-08-18 | 2007-01-31 | 于树春 | Medicinal composition for treating hepatitis B |
-
2010
- 2010-08-05 CN CN2010102454960A patent/CN102342995A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1903276A (en) * | 2006-08-18 | 2007-01-31 | 于树春 | Medicinal composition for treating hepatitis B |
Non-Patent Citations (2)
| Title |
|---|
| 王伯祥: "慢性乙型肝炎中医药证治研究进展", 《世界中医药》 * |
| 钟有添,王小丽,辜宝祥: "中医药治疗病毒性乙型肝炎研究进展", 《赣南医学院学报》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3015112A4 (en) * | 2013-11-27 | 2016-06-22 | Mingjie Liu | Medicament for treatment of hepatic ascites and preparation method therefor |
| CN116350695A (en) * | 2023-05-16 | 2023-06-30 | 杨洪印 | New use of pharmaceutical composition for treating pulmonary nodules |
| CN116350695B (en) * | 2023-05-16 | 2023-11-17 | 杨洪印 | New use of pharmaceutical composition for treating pulmonary nodules |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hou et al. | Origin and concept of medicine food homology and its application in modern functional foods | |
| CN112569332A (en) | Application of bupleurum tenue extract in treating viral pneumonia | |
| CN108057039A (en) | A kind of Dendrobium officinale polysaccharide and Siberian solomonseal rhizome polysaccharide composition and preparation method and application | |
| CN105012452A (en) | New application of clausena lansium leaves | |
| CN100400094C (en) | Traditional Chinese medicine for treating hepatitis B and its preparing process | |
| CN102125630A (en) | Traditional Chinese medicinal preparation for treating chronic hepatitis B and preparation method thereof | |
| CN102805840B (en) | Complex anti-tumor traditional Chinese medicine preparation | |
| CN103656122B (en) | Chinese medicine for the treatment of fever caused by exogenous pathogenic factors and preparation method thereof | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN102626443B (en) | Chinese herbal medicine combination for treating gout | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| CN102342995A (en) | Medicinal composition for treating liver cirrhosis and liver ascites and preparation method thereof | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN104274791A (en) | Compound Chinese medicinal granule for treatment of chicken indigestion and preparation method thereof | |
| CN104547026B (en) | Preparation method and application of salvia miltiorrhiza leave pseudo-ginseng extract | |
| CN104435658B (en) | A kind of medicine for ischemia apoplexy prevention and treatment and preparation method thereof | |
| CN106511584A (en) | Drug for treating postpartum fever | |
| CN103783524B (en) | A kind of Folium Forsythia buccal tablet and preparation method thereof | |
| CN106334171A (en) | Traditional Chinese medicine preparation for repairing liver damage and preparation method thereof | |
| CN101549140B (en) | Traditional Chinese medicine composition for treating AIDS and preparation method thereof | |
| CN102048858A (en) | Medicine composition for treating cirrhosis, hepatic ascites and liver cancer | |
| CN103705731A (en) | Traditional Chinese medicine composition for treating chronic alcoholic toxic liver disease | |
| CN114272349A (en) | Traditional Chinese medicine composition for tonifying spleen and nourishing liver and preparation method and application thereof | |
| CN103768450B (en) | A kind of Chinese medicine composition and preparation method thereof, preparation and application | |
| CN103816399A (en) | Traditional Chinese medicinal preparation for treating canine distemper |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120208 |